DUSP5 and cancer: One of this study’s key findings of this study is an identification of DUSP5 (dual specificity phosphatase 5) that associated significantly with BW loss in DOX-treated BXDs as well as with HF outcomes in humans, offering an intriguing potential implication for DUSP5 in mitigating various anti-cancer drug-induced cardiotoxicities.